Document is current

Article History

Received: 10 January 2024

Accepted: 12 February 2024

First Online: 20 February 2024

Declarations

:

: The PEP++ study has gone before and been approved by institutional review boards in Bangladesh, Brazil, India, and Nepal under the names of the national Principal Investigators. It has also been reviewed favourably by the Bangladesh Medical Research Council, Indian Council of Medical Research, and Nepal Health Research Council. Each index case, close contact and blanket contact approached in the project receives verbal and written study information from the research assistants and be requested to sign a paper informed consent form (ICF). Participants receive details on possible side effects from the antibiotics and have the right to refuse participation or withdraw informed consent at any point in the study. When dealing with a child/adolescent under the age of 18 or a person with mental disabilities, the ICF will be presented to and signed by the legal guardian. The ICFs will be stored and catalogued according to the national requirements of each country. The PEP++ clinical trial and project are registered on Dutch Trial Register, under trial registration NL7022 (formerly NTR7221) with the title <i>Stop the Transmission of Leprosy.</i> It was originally registered on April 12, 2018, and last updated on August 18, 2022. ExternalRef removed.

: Not applicable.

: The authors declare no competing interests.